Dra. Rosa Noguera Salvá

Investigador Principal
Grupo de Investigación Translacional de Tumores Sólidos Pediátricos

Presentación

Investigador
Principal
Dra. Rosa Noguera Salvá

rosa.noguera@uv.es  

Publicaciones
SuperHistopath: a deep learning pipeline for mapping tumor heterogeneity on low-resolution whole-slide digital histopathology images. Zormpas Petridis K, Noguera R, Ivankovic D, Kolarevic R, Jamin Y, Yuan Y. Frontiers in Oncology. 2021 Jan 20;10:586292. doi: 10.3389/fonc.2020.586292. PMID: 33552964

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Siaw J, Javanmardi N, Van den Eynden J, Lind D, Fransson S, Martinez-Monleon A, Djos A, Sjoberg R, Ostensson M, Caren H, Troen G, Beiske K, Berbegall Beltrán A, Noguera Salva R, Lai W, Kogner P, Palmer R, Hallberg B, Martinsson T. Cell Reports. 2020 Sep 22;32(12):108171. doi: 10.1016/j.celrep.2020.108171. PMID: 32966799

A three-dimensional bioprinted model to evaluate the effect of stiffness on neuroblastoma cell cluster dynamics and behavior. Monferrer Garzarán E, Martín Vañó S, Carretero Martínez A, Garcia-Lizarribar A, Burgos Panadero R, Navarro Fos S, Samitier J, Noguera Salva R. Scientific Reports. 2020 Apr 14;10(1):6370. doi: 10.1038/s41598-020-62986-w. PMID: 32286364

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Ambros I, Tonini G, Potschger U, Gross N, Mosseri V, Beiske K, Berbegall A, Benard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh E, Hogarty M, Monclair T, Holmes K, Valteau-Couanet D, Castel V, Tweddle D, Park J, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson A, Ambros P. Journal of Clinical Oncology. 2020 Nov 1;38(31):3685-3697. doi: 10.1200/JCO.18.02132. PMID: 32903140

Digital Image Analysis Applied to Tumor Cell Proliferation, Aggressiveness, and Migration-Related Protein Synthesis in Neuroblastoma 3D Models. Monferrer Garzarán E, Sanegre Sans S, Martín Vañó S, Garcia-Lizarribar A, Burgos Panadero R, Lopez Carrasco M, Navarro Fos S, Samitier J, Noguera Salva R. International Journal of Molecular Sciences. 2020 Nov 17;21(22):8676. doi: 10.3390/ijms21228676. PMID: 33212997

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes. Fernandez Blanco B, Berbegall A, Martín Vañó S, Castel V, Navarro Fos S, Noguera Salva R. Neoplasia. 2020 Nov 12;23(1):12-20. doi: 10.1016/j.neo.2020.11.001. PMID: 33190090

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line. Journal of Experimental & Clinical Cancer Research. 2020 Oct 28;39(1):226. doi: 10.1186/s13046-020-01729-1. PMID: 33109237

Integrating the Tumor Microenvironment into Cancer Therapy. Sanegre Sans S, Lucantoni F, Burgos Panadero R, De La Cruz-Merino L, Noguera Salva R, Alvaro Naranjo T. Cancers. 2020 Jun 24;12(6):1677. doi: 10.3390/cancers12061677. PMID: 32599891

Potential Molecular Players of the Tumor Microenvironment in Extracranial Pediatric Solid Tumors. Noguera R, Alvaro Naranjo. Cancers. 2020 Oct 9;12(10):2905. doi: 10.3390/cancers12102905. PMID: 33050312

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages. Juan Ribelles A, Barberá S, Yáñez Y, Gargallo P, Segura V, Juan B, Noguera Salva R, Piqueras M, Fornés-Ferrer V, Font de Mora J, Cañete A, Castel V. Scientific Reports. 2020 Jan 31;10(1):1914. doi: 10.1038/s41598-020-58428-2. PMID: 32005943

The topology of vitronectin: A complementary feature for neuroblastoma risk classification based on computer-aided detection. Vicente-Munuera P, Burgos Panadero R, Noguera I, Navarro Fos S, Noguera Salva R, Escudero L. International Journal of Cancer. 2020 Jan 15;146(2):553-565. doi: 10.1002/ijc.32495. PMID: 31173338

Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages. Ribelles AJ, Barberá S, Yáñez Y, Gargallo P, Segura V, Juan B, Noguera R, Piqueras M, Fornés-Ferrer V, Font de Mora J, Cañete A, Castel V. Scientific Reports. 2019 Sep 24;9(1):13806. doi: 10.1038/s41598-019-50327-5. PMID: 31551474

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis. Martinez-Ciarpaglini C, Machado I, Yoshida A, Nieto G, Berbegall AP, Blanquer-Maceíras MT, Noguera R, Ferrández A, Navarro S. International Journal of Surgical Pathology. 2019 Aug;27(5):568-573. doi: 10.1177/1066896919835945. PMID: 30907195

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. Monferrer E, Burgos-Panadero R, Blanquer-Maceiras M, Cañete A, Navarro S, Noguera R. BMC Cancer. 2019 Jan 3;19(1):1. doi: 10.1186/s12885-018-5219-3. PMID: 30606139

The tumour microenvironment as an integrated framework to understand cancer biology. Burgos-Panadero R, Lucantoni F, Gamero-Sandemetrio E, Cruz-Merino L, Álvaro T, Noguera R. Cancer Letters. 2019 Oct 1;461:112-122. doi: 10.1016/j.canlet.2019.07.010. PMID: 31325528

Therapeutic Opportunities in Neuroblastoma Using Nanotechnology. Rodríguez-Nogales C, Noguera R, Couvreur P, Blanco-Prieto MJ. Journal of Pharmacology and Experimental Therapeutics. 2019 Sep;370(3):625-635. doi: 10.1124/jpet.118.255067. PMID: 30635473

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma. Burgos-Panadero R, Noguera I, Cañete A, Navarro S, Noguera R. BMC Cancer. 2019 May 22;19(1):479. doi: 10.1186/s12885-019-5693-2. PMID: 31117974

Proyectos
Referencia: PI20/01107
Título: Neuroblastoma: estrategias mecanoterapéuticas basadas en modelos 3D y tumores derivados de pacientes con microambiente rico en vitronectina
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Rosa Noguera Salva
Duración: 2021 – 2023
Presupuesto: 232.320 €

Referencia: PI17/01558
Título: Identificación y validación de nuevas terapias, modelos preclínicos y marcadores de respuesta
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Rosa Noguera Salvá
Duración: 2018 – 2020
Presupuesto: 123.420 €

Referencia: CB16/12/00484
Título: CIBER Oncología
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Rosa Noguera Salvá
Duración: 2017 –
Presupuesto: 50.000 €

+ Información
Título: Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral con su matriz extracelular en tumores neuroblásticos
Doctorando: Burgos Panadero, Rebeca
Director: Noguera Salvá, Rosa; Navarro Fos, Samuel
Fecha: 31/07/2020
Universidad: Universitat de València